Glycomine, Inc.

Glycomine, Inc. is a U. S. -based biotechnology company focused on developing innovative therapies for rare genetic diseases, emphasizing treatments that restore protein function in patients, particularly those affected by PMM2-CDG.

Founded in 2014 and headquartered in San Carlos, California, Glycomine, Inc. specializes in therapies for rare genetic disorders. The company has engaged in four distinct funding rounds, with the most recent being a Series C round completed on July 22, 2024, raising USD 116. 945 mn.

The funding was co-led by Advent Life Sciences and CTI Life Sciences and included participation from notable investors such as Abingworth and Sanofi Ventures. The CEO of Glycomine is Peter McWilliams. Glycomine is dedicated to developing innovative replacement therapies for rare genetic diseases, particularly targeting PMM2-CDG (CDG Type 1a). Their leading product, GLM101, is a mannose-1-phosphate replacement therapy currently in clinical trials in the U.

S. and Europe. The product aims to deliver essential substrates to patients to restore disrupted protein function, thereby improving the quality of life for affected individuals. The primary clientele includes healthcare providers and institutions focusing on genetic disorders, alongside patients impacted by PMM2-CDG and related conditions in North America and Europe.

Glycomine's revenue model is primarily focused on the clinical development and potential commercialization of GLM101. The company has established strategic partnerships to advance its clinical trials, which may involve collaborations with healthcare organizations, research institutions, and pharmaceutical firms. Future revenue generation is anticipated from product sales, licensing deals, and milestones achieved during the drug development process, facilitating transactions through direct sales to healthcare providers or specialized distributors. In July 2024, Glycomine, Inc.

raised USD 116. 945 mn in Series C funding, aimed at supporting mid-stage clinical trials for GLM101 in patients with genetic disorders. This funding will facilitate the advancement of their lead product while the company explores market expansion opportunities in North America and Europe. Glycomine's strategic plans include launching new products in the near future, aligning with their goal to enhance treatment options for genetic diseases.